Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
GeNeuro SA logo — We focus on Human Endogenous Retroviruses (#HERVs) to fight...

GeNeuro SA

We focus on Human Endogenous Retroviruses (#HERVs) to fight neurodegeneration in #MS, #ALS and #LongCovid $GNRO

Founded 2006 17 employees Post-IPO Equity Total: $49.90M Biotechnology, Health Care +1

General Information

Company Name GeNeuro SA
Founded Year 2006
Founders / Decision Makers
Team member Team member
Employees 17
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with GeNeuro SA. To contact GeNeuro SA, visit geneuro.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does GeNeuro SA compare?

A PDF of GeNeuro SA and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting GeNeuro SA soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About GeNeuro SA

>GeNeuro SA> is a biotechnology company that was established in >2006> and is focused on developing innovative treatments for inflammatory and neurodegenerative disorders linked with Human Endogenous Retroviruses (HERVs). The company's slogan, >"We focus on Human Endogenous Retroviruses (#HERVs) to fight neurodegeneration in #MS, #ALS and #LongCovid $GNRO,"> highlights their dedication to combat the progression of disability in conditions such as Multiple Sclerosis (#FightMS) and other neurodegenerative diseases (#ALS #LongCOVID). In >February 2024>, GeNeuro SA secured a >€5.00M> post-IPO equity investment, with >Servier> and >Institut Merieux> as the primary investors. This funding is a testament to the company's potential and the confidence that reputable investors have in their vision and mission. As a company operating in the >Biotechnology> and >Health Care> sectors, GeNeuro SA is actively contributing to the advancement of treatments for critical medical conditions. Their commitment to addressing the challenges posed by neurodegenerative disorders associated with HERVs underscores their determination to make a meaningful impact in the healthcare industry.

Business keywords: neurodegeneration, Multiple Sclerosis, ALS, Long COVID, inflammatory disorders, Human Endogenous Retroviruses, treatment development, disability progression, innovative treatments, medical research, pharmaceuticals, biotech startups

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity €5.00M 2
Servier, Institut Merieux
01 Feb 2024
Post IPO Debt €7.00M 1
European Investment Bank
07 Mar 2023
Post IPO Equity €7.70M 2
Invesco
Invesco, Institut Merieux
12 May 2022
Grant Fr.6.70M 1
Federal Office of Public Health (FOPH) Switzerland
13 Dec 2021
Post IPO Equity €6.00M -
14 Jul 2021
Post IPO Equity €17.50M -
31 Jan 2020
Venture Round Undisclosed 1
Eclosion SA
Eclosion SA
01 Aug 2008

GeNeuro SA Alternatives & Competitors

View All Alternatives
GeNeuro SA vs
Rewind Therapeutics
Rewind Therapeutics

Pioneering novel treatments for neurological diseases, advancing the way to effective remyelination...

Series A
2-10 employees
Biotechnology, Health and Wellness
GeNeuro SA vs
BIOCAD
BIOCAD Russia

Science for life!

804 employees
Biotechnology, Health Care
GeNeuro SA vs
Biogen
Biogen United States

Innovative therapies worldwide for people living with serious neurological and neurodegenerative dis...

IPO
7823 employees
Biotechnology, Health Care
Also compare with: GeNeuro SA vs Texas Original Texas Original View all alternatives

FAQ About GeNeuro SA

We focus on Human Endogenous Retroviruses (#HERVs) to fight neurodegeneration in #MS, #ALS and #LongCovid $GNRO
GeNeuro SA was founded in 2006.
GeNeuro SA operates in Biotechnology, Health Care and Health and Wellness. Its work centres on neurodegeneration, Multiple Sclerosis, ALS and Long COVID.
GeNeuro SA has approximately 17 employees.
GeNeuro SA has completed 7 funding rounds, raising a total of $49.90M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to GeNeuro SA include Rewind Therapeutics, BIOCAD, Biogen, Apitope, Texas Original. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
GeNeuro SA and Rewind Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for GeNeuro SA, https://bouncewatch.com/company/geneuro-sa, updated 29 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes